Chemoradiotherapy in rectal cancer and pathological response
DOI:
https://doi.org/10.19230/jonnpr.3812Keywords:
chemoradiotherapy, cancer of rectum, radiotherapy, cancerAbstract
Introduction. Neoadjuvant treatment with radiotherapy and radiosensitizing chemotherapy in locally advanced rectal cancer (LARC) significantly decreases local recurrence rates. Therefore the objective of this study is to analyze the pathological complete response (PCR) and partial response (PPR) of neoadjuvant treatment with exclusive chemoradiotherapy in patients with locally advanced rectal cancer.
Matherial and Method. It has been made a study descriptive, retrospective in a cohort of patients with LARC in the January 2016 to December 2018 period in the Radiation-Oncology Department of Hospital Universitario La Paz. 140 patients were included. A group of patients (92,9%) received treatment with radiotherapy 3D conformed technique with a dose administered the 45 Gy on pelvis and a boost of 5,4 Gy on tumor and other group (7,1%) received treatment with volumetric archotherapy radiotherapy (VMAT) guided by image (IGRT) with a dose administered of 53,7% on pelvis with concurrent boost and. The dose of capecitabine was 850 mg/m2, twice a day during the treatment. The patients were re-evaluated with post-neoadjuvant MRI. Patients were operated 6 to 8 weeks post chemoradiotherapy.
Results. CPR was obtained of 17,1% and pPR of 80,1% with a global rate downstaging of 31,8%.
Conclusion. It concludes that chemoradiotherapy neoadjuvant is a safe treatment with acceptable rates of local control in patients with LARC.
Downloads
References
Las cifras del cáncer en España 2018. Sociedad Española de Oncología Médica. Disponible en: https://seom.org/seomcms/images/stories/recursos/Las_Cifras_del_cancer_en_Espana2018.pd [Consultado el 05 de marzo del 2020]
R. Glynne-Jones, L. Wyrwicz, E. Tiret, G. Brown, C. Rödel, A. Cervantes and D. Arnold. Rectal Cancer: ESMO Clinical Practice Guidelines. Ann Oncol (2017).
Habr-Gama A, Perez R, Proscurshim I, Gama-Rodrigues J. Complete clinical response after neoadjuvant chemoradiation for distal rectal cancer. Surg Oncol Clin N Am. 2010 Oct;19(4):829-45. doi: 10.1016/j.soc.2010.08.001.
Smith FM, Waldron D, Winter DC.Rectum-conserving surgery in the era of chemoradiotherapy. Br J Surg. 2010 Dec;97(12):1752-64. doi: 10.1002/bjs.7251.
Fiona Taylor;Philip Quirke;Richard Heald;Brendan Moran;Lennart Blomqvist;Ian Swift;David Sebag- Montefiore;Paris Tekkis;Gina Brown. Preoperative High-resolution Magnetic Resonance Imaging Can Identify Good Prognosis Stage I, II, and III Rectal Cancer Best Managed by Surgery Alone: A Prospective, Multicenter, European Study. Annals of Surgery. 253(4):711–719, APRIL 2011. DOI: 10.1097/SLA.0b013e31820b8d52
Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, Campos FG, Kiss DR, Gama- Rodrigues J. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004 Oct;240(4):711-7; discussion 717-8. DOI: 10.1097/01.sla.0000141194.27992.32
Habr-Gama A, Perez RO, São Julião GP, Proscurshim I, Gama-Rodrigues J. Nonoperative approaches to rectal cancer: a critical evaluation. Semin Radiat Oncol. 2011 Jul;21(3):234-9. doi: 10.1016/j.semradonc.2011.02.010
Natally Horvat , Camila Carlos Tavares Rocha, Brunna Clemente Oliveira, Iva Petkovska, Marc J. Gollub. MRI of Rectal Cancer: Tumor Staging, Imaging Techniques, and Management. RadioGraphics. Vol. 39, No. 2. Feb 15, 2019.
Delli Pizzi A, Basilico R, Cianci R, Seccia B, Timpani M, Tavoletta A, Caposiena D, Faricelli B, Gabrielli D, Caulo M. Rectal cancer MRI: protocols, signs and future perspectives radiologists should consider in everyday clinical practice. Insights Imaging. 2018 Aug;9(4):405-412.
Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A, Widmar M, Ganesh K, Yaeger R, Cercek A, Weiser MR, Nash GM, Guillem JG, Temple LKF, Chalasani SB, Fuqua JL, Petkovska I, Wu AJ, Reyngold M, Vakiani E, Shia J, Segal NH, Smith JD, Crane C, Gollub MJ, Gonen M, Saltz LB, Garcia-Aguilar J, Paty PB. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. JAMA Oncol. 2019 Apr 1;5(4):e185896. doi: 10.1001/jamaoncol.2018.5896. Epub 2019 Apr 11.
Habr-Gama A, Perez RO, Proscurshim I, Campos FG, Nadalin W, Kiss D, Gama-Rodrigues J. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg. 2006 Dec;10(10):1319-28; discussion 1328-9.
Regina Beets-Tan and Geerard Beets. Rectal Cancer: Review with Emphasis on MR Imaging. August 2004 Radiology, 232, 335-346.
Beets-Tan RG, Beets GL, Vliegen RF, Kessels AG, Van Boven H, De Bruine A, von Meyenfeldt MF, Baeten CG, van Engelshoven JM. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 357:497-504, 2001.
Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis. Radiology. 2004 Sep;232(3):773-83. Epub 2004 Jul 23.
Glynne-Jones R1, Wallace M, Livingstone JI, Meyrick-Thomas J. Complete clinical response after preoperative chemoradiation in rectal cancer: is a "wait and see" policy justified? Dis Colon Rectum. 2008 Jan;51(1):10-9; discussion 19-20. Epub 2007 Nov 28.
Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012 Jul;99(7):918-28. doi: 10.1002/bjs.8702. Epub 2012 Feb 23.
Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005 Dec 1;23(34):8688-96. Epub 2005 Oct 24. DOI: 10.1200/JCO.2005.02.1329
O'Neill BD, Brown G, Heald RJ, Cunningham D, Tait DM. Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol. 2007 Jul;8(7):625-33. DOI: 10.1016/S1470-2045(07)70202-4
Zhou ZR, Liu SX, Zhang TS, Chen LX, Xia J, Hu ZD, Li B. Short-course preoperative radiotherapy with immediate surgery versus long-course chemoradiation with delayed surgery in the treatment of rectal cancer: a systematic review and meta-analysis. Surg Oncol. 2014 Dec; 23(4):211-21.
Liu SX, Zhou ZR, Chen LX, Yang YJ, Hu ZD, Zhang TS. Short-course Versus Longcourse Preoperative Radiotherapy plus Delayed Surgery in the Treatment of Rectal Cancer: a Meta-analysis. Asian Pac J Cancer Prev. 2015; 16(14):5755-62.
Ceelen W, Fierens K, Van Nieuwenhove Y, Pattyn P. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: a systematic review and meta-analysis. Int J Cancer. 2009 Jun 15; 124(12):2966-72.
De Caluwé L, Van Nieuwenhove Y, Ceelen WP. Preoperative chemoradiation versus radiation alone for stageII and III resectable rectal cáncer. Cochrane Database of Systematic Reviews2013, Issue 2. Art. No.: CD006041
Wang X, Zheng B, Lu X, Bai R, Feng L, Wang Q, Zhao Y, He S. Preoperative shortcourse radiotherapy and long- course radiochemotherapy for locally advanced rectal cancer: Meta-analysis with trial sequential analysis of long- term survival data. PLoS One. 2018 Jul 12;13(7):e0200142. doi: 10.1371/journal.pone.0200142. eCollection 2018.
Glehen O, Chapet O, Adham M, Nemoz JC, Gerard JP; Lyons Oncology Group. Longterm results of the Lyons R90-01 randomized trial of preoperative radiotherapy with delayed surgery and its effect on sphincter-saving surgery in rectal cancer. Br J Surg. 2003 Aug;90(8):996-8. DOI: 10.1002/bjs.4162
Kalady MF, de Campos-Lobato LF, Stocchi L, Geisler DP, Dietz D, Lavery IC, Fazio VW. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009 Oct;250(4):582-9. doi: 10.1097/SLA.0b013e3181b91e63.
Habr-Gama A, Perez RO, São Julião GP, Proscurshim I, Gama-Rodrigues J. The need for effective radiosentitizing agents: experience in patients with complete pathological response. Anticancer Drugs. 2011 Apr;22(4):308-10. Doi: 10.1097/CAD.0b013e3283428193.
D. Pettersson, E. Lörinc, T. Holm, H. Iversen, B. Cedermark, B. Glimelius, ,and A. Martling. Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. Br J Surg. 2015 Jul; 102(8): 972– 978. doi: 10.1002/bjs.9811
Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM; Timing of Rectal Cancer Response to Chemoradiation Consortium. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011 Jul;254(1):97-102. doi: 10.1097/SLA.0b013e3182196e1f.
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
